MBX-102

C₁₉H₁₇ClF₃NO₄

415.79

NA.77

MBX-102 may be used in PPAR-mediated cell signaling studies.

MBX-102 has a potent transrepression effect on PPARγ. It is an oral glucose-reducing agent and also has insulin-sensitizing properties. It is useful as treatment for type 2 diabetes. MBX-102 also lowers triglycerides in a PPARα-independent manner.
MBX-102 is a selective PPAR modulator (SPPARM) and has been shown to inhibit phosphorylation of PPARγ. MBX-102 is converted to the active form, MBX-102 acid, in vivo.

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
This compound is featured on the Nuclear Receptors (Non-Steroids) and Nuclear Receptors (PPARs) pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

100

≥98% (HPLC)

powder

white to tan

DMSO: ≥35 mg/mL

Johnson & Johnson

2-8℃

5, 25 mg in glass bottle

GHS06,GHS09

Danger

H301 - H319 - H400

P273 - P301 + P310 + P330 - P305 + P351 + P338

Acute Tox. 3 Oral - Aquatic Acute 1 - Eye Irrit. 2

6.1D - Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

WGK 3